Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Sep;18(3):194-198.
doi: 10.1097/CU9.0000000000000226. Epub 2024 Sep 20.

Does dutasteride reduce the bleeding in transurethral resection of the prostate in patients on antiplatelet drugs?

Ahmed M Rammah  1 , Alaa Meshref  1 , Ebram Soliman  2 , Islam Nasser Abd Elaziz  1 , Enmar Habib  1 , Ahmed Yehia Abdelaziz  1 , Ahmed H Abozamel  1
Affiliations

Does dutasteride reduce the bleeding in transurethral resection of the prostate in patients on antiplatelet drugs?

Ahmed M Rammah et al. Curr Urol. 2024 Sep.

Abstract

Background: The aim of this study was to assess the effect of a 4-week dutasteride treatment on reducing the intraoperative and postoperative bleeding, as well as the amount and duration of irrigation required to clear the urine after transurethral resection of the prostate (TURP) ≥50 g in men receiving the antiplatelet drug (APD).

Materials and methods: This double-blind randomized clinical trial included patients with a prostate size ≥50 g who were indicated for TURP and were already receiving APD. The study was conducted in the Urology Department of Cairo University over a 12-month period. Routine preoperative laboratory investigations were performed in all patients. Moreover, baseline prostate size, serum prostate-specific antigen level, and International Prostate Symptom Score were estimated. The patients were randomly divided into 2 equal groups (groups A and B). Group A, the dutasteride group, received dutasteride (0.5 mg) once daily for 4 weeks. Group B, the placebo group, received a placebo capsule once daily for 4 weeks. Both groups underwent bipolar TURP. Fifteen patients were excluded from the study; 9 patients from group A and 6 patients from group B, either due to drug intolerability or loss follow-up.

Results: The mean blood loss was insignificant between the 2 groups immediately after and 24 hours after surgery (Δ hemoglobin: 1.41 ± 0.63 g/dL vs. 1.48 ± 0.54 g/dL, 2.12 ± 0.70 g/dL vs. 2.31 ± 0.78 g/dL, respectively, p = 0.631, p = 0.333; Δ hematocrit: 2.97% ± 1.51% vs. 3.16% ± 1.36%, 4.96% ± 1.87% vs. 5.73% ± 4.39%, respectively, p = 0.610, p = 0.380). However, there were significant differences in duration of indwelling urethral catheter (5.10 ± 0.55 days vs. 5.80 ± 1.79 days, p = 0.048), duration of bladder irrigation (13.60 ± 2.85 hours vs. 16.33 ± 6.62 hours, p = 0.044), and the amount of saline used for bladder irrigation (11.03 ± 2.30 L vs. 13.87 ± 6.13 L, p = 0.046) between group A and group B. respectively.

Conclusions: Treatment with dutasteride for 4 weeks before TURP in men receiving APD did not significantly reduce intraoperative or postoperative bleeding after TURP but could significantly reduce the duration of indwelling catheter placement, as well as the duration and amount of saline irrigation.

Keywords: Antiplatelet drugs; Dutasteride; Postprostatectomy bleeding; Transurethral resection of the prostate.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Flowchart demonstrating the consort criteria of our study.
See this image and copyright information in PMC

References

    1. Srinivasan A, Wang R. An update on minimally invasive surgery for benign prostatic hyperplasia: Techniques, risks, and efficacy. World J Mens Health 2020;38(4):402–411. - PMC - PubMed
    1. Cayuelas Rubio C Pallás Costa Y Juan Escudero J, et al. Minimally invasive treatment for lower urinary tract symptoms due to benign prostatic hyperplasia. Our initial experience with Urolift® under local anaesthesia and sedation. Actas Urol Esp (Engl Ed) 2019;43(9):488–494. - PubMed
    1. Zaitsu M Tonooka A Mikami K, et al. A dual 5α-reductase inhibitor dutasteride caused reductions in vascular density and area in benign prostatic hyperplasia. ISRN Urol 2013;2013:863489. - PMC - PubMed
    1. Kravchick S, Cytron S, Mamonov A, Peled R, Linov L. Effect of short-term dutasteride therapy on prostate vascularity in patients with benign prostatic hyperplasia: A pilot study. Urology 2009;73(6):1274–1278. - PubMed
    1. Rühle A Blarer J Oehme F, et al. Safety and effectiveness of bipolar transurethral resection of the prostate in patients under ongoing oral anticoagulation with coumarins or antiplatelet drug therapy compared to patients without anticoagulation/antiplatelet therapy. J Endourol 2019 Jun;33(6):455–462. - PubMed

LinkOut - more resources